Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance

다국어 초록 (Multilingual Abstract)

Purpose The purpose of this study was to subdivide M1 stage nasopharyngeal carcinoma (NPC) patients with bone-only metastases for prognosis prediction while identifying the treatment effect of locoregional radiotherapy (LRRT) and metastasis radiotherapy (MRT) among patients with different risk.
Materials and Methods From November 2006 to October 2016, a total of 226 patients with bone-only metastasic NPC were retrospectively enrolled. All patients developed distant lesions before receiving treatment. All potential prognostic factors were considered and the correlation of the M1 subdivisions with overall survival (OS) was determined by Cox regression hazards model.
Kaplan-Meier curves were used to appraise survival condition and log-rank testing was used to compare the differences.
Results The median follow-up time was 33.9 months (range, 3 to 126 months). According to multivariate Cox proportional hazard analysis, the number of metastatic lesions and Epstein-Barr virus (EBV) DNA status after palliative chemotherapy (PCT) were independent prognostic factors for OS. Thus, we subdivided patients into three risk groups according to these two factors. Systemic chemotherapy combined with LRRT may benefit patients in low- and intermediate-risk groups but not in the high-risk group. Further aggressive MRT based on systemic chemotherapy showed no survival benefit in any risk group.
Conclusion The stratification of NPC patients with bone-only metastasis based on EBV DNA after PCT and the number of metastatic lesions provided promising prognostic value and could aid clinicians in person-specific treatment.

참고문헌 (Reference)

1 Chen C, "Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma" 71 : 371-378, 2013

2 Yeh SA, "Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma : benefits of primary radiotherapy" 36 : 132-136, 2006

3 Bensouda Y, "Treatment for metastatic nasopharyngeal carcinoma" 128 : 79-85, 2011

4 Liu LT, "The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma" 93 : 862-869, 2015

5 Trilling GM, "Spinal metastasis in head and neck cancer" 4 : 36-, 2012

6 Zeng L, "Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors" 9 : e108070-, 2014

7 Sun Y, "Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensitymodulated radiotherapy" 110 : 390-397, 2014

8 Lo YM, "Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma" 59 : 1188-1191, 1999

9 Lin JC, "Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma" 350 : 2461-2470, 2004

10 Tang LQ, "Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging" 31 : 2861-2869, 2013

11 Lim A, "Prolonged remission in a patient with nasopharyngeal carcinoma with a solitary bone metastasis" 29 : e135-e137, 2011

12 He S, "Pretreatment alkaline phosphatase and Epstein-Barr virus DNA predict poor prognosis and response to salvage radiotherapy in patients with nasopharyngeal carcinoma and metachronous bone-only metastasis" 8 : 417-424, 2017

13 An X, "Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy" 117 : 3750-3757, 2011

14 Chan AT, "Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma" 94 : 1614-1619, 2002

15 Shen L, "M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma" 20 : 291-298, 2015

16 Fandi A, "Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type" 18 : 1324-1330, 2000

17 Khot A, "Long-term disease control in a patient with recurrent bone-only oligometastatic nasopharyngeal carcinoma" 34 : e25-e26, 2016

18 Chen MY, "Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis" 32 : 604-613, 2013

19 Pfister DG, "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines" 11 : 917-923, 2013

20 Torre LA, "Global cancer statistics, 2012" 65 : 87-108, 2015

21 Zou X, "Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment" 77 : 117-126, 2017

22 Ong YK, "Design of a prognostic index score for metastatic nasopharyngeal carcinoma" 39 : 1535-1541, 2003

23 Lee AW, "Current management of nasopharyngeal cancer" 22 : 233-244, 2012

24 Leung SF, "Clinical features and management of distant metastases of nasopharyngeal carcinoma" 20 : 27-29, 1991

25 Pan CC, "Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma : a study of 1027 cases and review of the literature" 4 : 334-338, 2012

26 Knudson G, "Bone scan as a stratification variable in advanced prostate cancer" 68 : 316-320, 1991

27 Yoon A, "Bone metastasis in primary endometrial carcinoma : features, outcomes, and predictors" 24 : 107-112, 2014

28 Bhandari V, "A retrospective study of incidence of bone metastasis in head and neck cancer" 9 : 90-93, 2013

29 Ji JH, "A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)" 48 : 3198-3204, 2012

30 Chen C, "A prognostic score for nasopharyngeal Carcinoma with bone metastasis : development and validation from multicenter" 9 : 797-806, 2018